Verastem, Inc. (VSTM) stock
VSTMNasdaqPharmaceutical PreparationsFiscal year ends December 31
$7.41−0.29 (-3.77%)
Close on Nov 17, 2026Market cap $671.08MP/E –Yield –
Earnings
Verastem's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Feb 3, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q2 FY2026
$40.10M
Adjusted EPS, Q2 FY2026
-$0.35
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Verastem's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 3, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Oct 14, 2026before the open | – | – | – | – | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 6, 2026after the close | $40.10M | – | -$0.35 | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 4, 2026before the open | $17.50M | – | – | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 4, 2025before the open | $11.20M | – | -$1.35 | -$0.54 | Release |
| Q4 FY2024ended Dec 31, 2024 | Jan 13, 2025before the open | – | – | – | – | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 2, 2023before the open | – | – | – | – | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 8, 2022before the open | $0 | – | -$0.12 | -$0.11 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 28, 2022before the open | – | – | – | – | Release |
| Q2 FY2020ended Jun 30, 2020 | Aug 10, 2020before the open | – | – | – | – | Filing |
| Q1 FY2020ended Mar 31, 2020 | Apr 27, 2020before the open | – | – | – | – | Filing |
| Q4 FY2019ended Dec 31, 2019 | Feb 28, 2020before the open | – | – | – | – | Filing |
| Q3 FY2019ended Sep 30, 2019 | Oct 29, 2019after the close | – | – | – | – | Filing |
| Q4 FY2015ended Dec 31, 2015 | Mar 3, 2016before the open | – | – | – | – | Filing |
| Q3 FY2015ended Sep 30, 2015 | Nov 9, 2015after the close | – | – | – | – | Filing |
| Q4 FY2014ended Dec 31, 2014 | Mar 10, 2015before the open | – | – | – | – | Filing |
| Q4 FY2013ended Dec 31, 2013 | Mar 6, 2014during market hours | – | – | – | – | Filing |
| Q4 FY2012ended Dec 31, 2012 | Mar 27, 2013during market hours | – | – | – | – | Filing |
| Q2 FY2012ended Jun 30, 2012 | Aug 15, 2012during market hours | – | – | – | – | Filing |
| Q1 FY2012ended Mar 31, 2012 | May 14, 2012before the open | – | – | – | – | Filing |
| Q4 FY2011ended Dec 31, 2011 | Mar 14, 2012before the open | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Verastem has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Verastem puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Verastem filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Results
- Results
- Results
- Update
- Results
- Update
- Update
- Update
- Update
- Results
- Delivering Novel Therapies for RAS/MAPK Pathway - Driven Cancers CORPORATE PRESENTATION JANUARY 2026Update
- Update
- Update
- News
See a number that looks wrong?